Innate Pharma (IPHA) Common Equity (2017 - 2025)

Innate Pharma (IPHA) has reported Common Equity for 9 consecutive years, with -$24.7 million the latest figure, recorded in Q4 2025.

• Quarterly Common Equity fell 345.69% year-over-year to -$24.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$24.7 million (down 345.69% YoY) and the FY2025 annual result came in at -$24.7 million, down 345.69% from the prior year.
• Common Equity fell to -$24.7 million in Q4 2025 per IPHA's latest filing, from $5.9 million in the prior quarter.
• Over the last five years, Common Equity for IPHA reached as high as $152.0 million in Q2 2021 and fell as low as -$24.7 million in Q4 2025.
• A 5-year average of $61.7 million and a median of $60.3 million in 2022 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2023 — Common Equity declined 4.16% — and 2025, when it slumped 345.69%.
• Year by year, Common Equity stood at $122.3 million in 2021, then plunged by 49.6% to $61.6 million in 2022, then dropped by 4.16% to $59.1 million in 2023, then plunged by 82.98% to $10.1 million in 2024, then slumped by 345.69% to -$24.7 million in 2025.
• According to Business Quant data, Common Equity over the past three periods registered -$24.7 million, $5.9 million, and $10.1 million for Q4 2025, Q2 2025, and Q4 2024 respectively.